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KEY POINTS 
- The amino acid transporter TAT1 (Slc16A10) mediates facilitated diffusion of 
aromatic amino acids across membranes. 
- TAT1 null mice lack liver control of aromatic amino acids and display altered 
epithelial amino acid transport. 
- The data support the hypothesis that equilibrative transport of essential amino acids by 
TAT1 is crucial for body amino acid homeostasis control. 
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ABSTRACT 
    The uniporter TAT1 (Slc16a10) mediates the facilitated diffusion of aromatic 
amino acids across basolateral membranes of kidney, small intestine and liver 
epithelial cells and across the plasma membrane of non-epithelial cells like skeletal 
myocytes. Its role for body amino acid homeostasis was now investigated using 
newly generated TAT1 (Slc16a10) defective mice (tat1-/-). These mice grow and 
reproduce normally, show no gross phenotype and no obvious neurological defect. 
Histological analysis did not reveal abnormalities and there is no compensatory 
change in any tested amino acid transporter mRNA. TAT1 null mice display 
however increased plasma, muscle and kidney aromatic amino acid concentration 
under both normal and high protein diet, although this concentration remains 
normal in liver. A major aromatic aminoaciduria and a smaller urinary loss of all 
substrates additionally transported by L-type amino acid antiporter Lat2-4F2hc 
(Slc7a8) were revealed under high protein diet. This suggests an epithelial 
transport defect as also shown by the accumulation of intravenously injected 123I-2-
I-L-Phe in kidney and of 3H-L-Phe in ex vivo everted gut sac enterocytes. Taken 
together, these data indicate that the uniporter TAT1 is required to equilibrate the 
concentration of aromatic amino acids across specific membranes. For instance, it 
enables hepatocytes to function as sink that controls the extracellular aromatic 
amino acid concentration. Additionally, it facilitates the release of aromatic amino 
acids across the basolateral membrane of small intestine and proximal kidney 
tubule epithelial cells, thereby allowing the efflux of other neutral amino acids 
presumably via Lat2-4F2hc. 
 
    Dietary and endogenous proteins are hydrolyzed in the gastrointestinal lumen to tri-
peptides, di-peptides and individual amino acids (AAs) that are taken up by small 
intestine enterocytes (Nassl et al., 2011). These cells hydrolyze the oligopeptides into 
single AAs and also further metabolize some of them. Finally, they release most AAs 
into the portal circulation, thereby strongly influencing the rate of AA appearance in 
plasma (Cynober, 2002; Wu, 2009). It is noteworthy that the amount of free AAs 
transported daily from the enterocytes into the circulation is much larger than the free 
AA pool of the plasma and extracellular space (~100 g per day versus less than 10 g), 
such that their uptake into tissues is crucial for maintaining extracellular AA 
homeostasis (Cynober, 2002). In the cells of different organs, AAs may then serve as 
 Aromatic amino acid transport and homeostasis  
 
 3 
building blocks for the synthesis of structural and functional proteins, may be used for 
cellular metabolism or function as signalling molecules (Verrey et al., 2009; Wu, 2009). 
Therefore, AA transfer across plasma membranes via various cooperating AA 
transporters plays a crucial role for body AA homeostasis and the defect of transporters 
leads to several diseases (Verrey et al., 2009; Broer & Palacin, 2011).  
    The best characterized basolateral AA transporters of the small intestine and proximal 
kidney tubule (re)absorbing epithelia are the abundant Lat2-4F2hc (Slc7a8) and y+Lat1-
4F2hc (Slc7a7) that function as obligatory exchangers (antiporters). Thus, they do not 
mediate net AA transport, but are suggested to perform the directional transport of all 
their substrate AAs in exchange for AAs that can be recycled across the membrane by 
parallel transporters able to mediate a directional flux (Pfeiffer et al., 1999; Rossier et 
al., 1999; Meier et al., 2002; Fernandez et al., 2003; Verrey, 2003; Verrey et al., 2009). 
The role of Lat2-4F2hc has been recently investigated in vivo using a lat2 defective 
mouse (Braun et al., 2011). Its phenotype was mild, presenting an increase in several 
small neutral AAs in serum and a corresponding minor aminoaciduria. Based on these 
published data we estimate that the observed small urinary AA loss of lat2 null mice is 
not due to a decreased fractional excretion of AAs and therefore surprisingly does not 
point to a substantial epithelial AA transport defect (Braun et al., 2011). Interestingly, 
aromatic amino acids (AAAs) were not elevated in the serum of lat2 null mice, 
suggesting that another AA transporter plays here a dominant role, possibly the T-type 
aromatic AA transporter TAT1 (Slc16a10) which was found slightly upregulated in the 
kidney of lat2 null animals. This transporter was molecularly identified and first 
characterized in 2001 by Endou and co-workers (Kim et al., 2001). In a later study, we 
have demonstrated using the Xenopus laevis oocyte expression system that TAT1 
functions as a facilitated diffusion pathway which mediates the transport of AAAs L-
Phe, L-Trp and L-Tyr with symmetric low apparent affinities, for instance with a K0.5 of 
approximately 30 mM for L-Phe influx and efflux (Ramadan et al., 2006). Interestingly, 
TAT1 protein was shown to co-localize in the kidney proximal tubule with the two 
exchangers mentioned above (Ramadan et al., 2007) and also to localize to the 
basolateral membrane of small intestine enterocytes and the sinusoidal membrane of 
perivenous hepatocytes (Ramadan et al., 2006). The analysis of tat1 mRNA expression 
by real time PCR revealed its presence in the epithelial tissues mentioned above and 
also in muscles and brain (Ramadan et al., 2006). Finally, it was demonstrated that 
AAAs effluxing via TAT1 can be recycled into the cell by the exchanger Lat2-4F2hc 
 Aromatic amino acid transport and homeostasis  
 
 4 
and thereby drive the efflux of other intracellular neutral AAs that are substrates of 
Lat2-4F2hc (Ramadan et al., 2007). To investigate the role that TAT1 plays in whole 
body AA homeostasis maintenance and in epithelial AA transport, we generated a 
TAT1 knock out (tat1-/-) mouse and present here its first characterization. 
 
EXPERIMENTAL PROCEDURES 
The tat1 knock out mouse model was produced by Ingenium Pharmaceuticals AG 
(Germany) using ENU (N-ethyl-N-nitrosurea) mutagenesis (Augustin et al., 2005; 
Keays et al., 2007). The nonsense mutation in the tat1 gene leads to a premature stop at 
position 88 (Y88*). The mice were backcrossed 10 times in a C57Bl/6J inbred strain 
(Charles River, Germany), which was the background of the parental female, whereas 
the mutagenized sperm was C3HeBFeJ. All animals were housed in standard conditions 
in normal light cycle and fed a standard diet prior to experiment. All procedures for 
mouse handling were according to the Swiss Animal Welfare laws and approved by the 
Kantonales Veterinäramt Zürich.  
    Immunofluorescence and real-time PCR. The anti-mTAT1 antibody used has been 
previously characterized (Ramadan et al., 2006) and tissues were processed as described 
elsewhere (Rossier et al., 1999). mRNA was extracted and quantified as described 
before (Ramadan et al., 2006) with the only difference that the reference gene used was 
HPRT (hypoxanthine guanine phosphoribosyl transferase). 
    RotaRod Test. Mice were put on a rotating drum with an accelerating (day 1, 6 to 60 
rpm) or fixed speed (day 2, average speed reached on day 1) (Ugo Basile, model 47600, 
Italy) (Sugiura et al., 2005). The time at which the animal drops off the drum was 
measured (maximal testing time: 300 s). Five trials were performed on each day. The 
average value from 4 different experimental days was calculated. 
    Different protein diets and metabolic cage experiments. Ten week old tat1-/- and wt 
littermate mice were fed sequentially with a normal protein diet (20% casein) followed 
by 8 days of high protein diet (40% casein). The modified standard diet AIN93G was 
maintained isocaloric by adjusting the starch content (Kliba-Nafg, Switzerland). Chow 
was put as pellet directly in the normal cages or reduced to powder for the metabolic 
cage experiment. Mice were daily weighed and put every third day into metabolic cages 
(Tecniplast, Buguggiate, Italy) from 08:30 to 16:30 to adapt, and 24 hours (08:30-
08:30) at the end of each diet period. At the end of the 24 hours, urine and faeces were 
collected and food and water consumption recorded. Urinary pH was measured using a 
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pH microelectrode (691 pH-meter, Metrohm). Urinary creatinine was measured by the 
Jaffe method (Seaton & Ali, 1984). Urinary and plasma urea were measured using the 
diacetyl monoxime method (Wybenga et al., 1971). Urinary electrolytes (Na+, K+, Ca2+, 
Mg2+, Cl-, SO42-) were measured by ion chromatography (Metrohm ion chromatograph, 
Switzerland). Blood was collected through a single tail tip cut into Na+-heparinised 
micro-haematocrit-tubes (Provet AG, Switzerland) and plasma collected after 
centrifugation at 6000 g at 4°C. Animals were anesthetized with Isoflurane (Provet AG, 
Switzerland) and sacrificed by decapitation. After sacrifice, organs were harvested, 
frozen in liquid nitrogen and stored at -80°C. For AA measurements, organs were lysed 
using MagNa Lyser Green Beads (Roche, Switzerland) in PBS supplemented with 1 
µl/ml Protease Inhibitor Cocktail (Sigma, Switzerland), in a ratio of wet weight to PBS 
volume of 1:3. Supernatant was collected after two 15’000 g centrifugations for 15 
minutes at 4°C. 
    Amino acids measurement. The analysis was done by the Functional Genomics 
Center Zurich (FGCZ). Samples were deproteinized with 10% sulfosalicylic acid and 
amino acid concentrations were determined using the MassTrak Amino Acid Analysis 
Solution (Waters, Milford, USA) according to the manufacturer’s instructions. The tat1-
/-
 plasma AA ratios represented in Fig. 3B were normalized to the wt ones that were 
measured within the same diet and that are directly depicted in Fig. 3A. The same 
procedure was used to obtain the normalized urinary values depicted in Fig. 5B.  
    Micro-SPECT/CT imaging and biodistribution analysis. Imaging and biodistribution 
of the aromatic amino acid analog 123I-2-I-L-Phe was performed in wt and tat-/- mice. 
123I-2-I-L-Phe was synthesized as described before (Bauwens et al., 2007). Animals 
injected with 123I-2-I-L-Phe were anesthetized and imaged 30 min after intravenous 
injection with a micro-SPECT (e.cam 180, Siemens) and a micro-CT (Skyscan 1178, 
Skyscan, Belgium) system as described before (Lahoutte et al., 2002; Lahoutte et al., 
2003; Lahoutte et al., 2004; Bauwens et al., 2007; Vanhove et al.). Images were 
visualized with the AMIDE 0.9.1 software, where MicroCT is represented in gray scale 
and MicroSPECT in NIH colour scale (Loening & Gambhir, 2003). After imaging, 
animals were sacrificed and dissected. All major organs and tissues were collected and 
counted in a gamma camera counter (Canberra, Belgium) and expressed as percentage 
of injected activity per gram of organ or tissue. 
    Everted gut sacs. Uptake on first 2/3 of proximal small intestine segments of 
radiolabeled L-Phe and D-Mannitol was performed as described elsewhere (Nassl et al., 
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2011). Shortly, everted gut sacs were incubated for 10 minutes at 37°C in bubbling 
(95% oxygen and 5% carbon dioxide) Krebs-Tris buffer (pH 7.4) containing 100 µM L-
Phe, 0.5 µCi 3H-L-Phe/mL (Hartmann Analytic, Germany), 0.02 µCi 14C-D-
Mannitol/mL (ARC, USA). After brief washing, sacs were cut open and content activity 
counted (serosa). Sacs were further dried at 55°C O/N on cellulose (Sartorius AG, 
Germany) and weighed. The sacs (tissue) were lysed in Solvable (Perkin Elmer, 
Switzerland) for 6 hours at 50°C, bleached with 200 µl of 30% H2O2, and the 
radioactivity was determined by liquid scintillation in 15 ml of Ultima Gold (Perkin 
Elmer, Switzerland). AA transport was expressed relative to the dry tissue weight.  
    Statistics. Statistical analysis was performed using GraphPad Prism 5.0 (GraphPad 
Software, USA) and R 2.14 (R Foundation of Statistical Computing). Unless mentioned 
otherwise, between-group comparisons were performed by Student's unpaired t-test or 
by repeated-measures one-way analysis of variance, followed by Bonferroni posttest. 
Statistical significance was accepted at P<0.05 or as indicated. Data are presented as 
means ± SEM. 
 
RESULTS 
A tat1 knockout mouse (tat1-/-) was produced by ENU mutagenesis (Ingenium 
Pharmaceuticals AG, Germany) in the context of the former European EUGINDAT 
project. The nonsense mutation (Y88*) was confirmed by DNA sequencing and the 
mice were backcrossed 10 times into C57Bl/6J background. Absence of tat1 expression 
was confirmed using immunofluorescence and mRNA analysis. The TAT1 protein was 
indeed not detected in any of the knock out samples tested (Fig. 1, B and D) and the tat1 
mRNA levels were decreased in all tested tissues, but in white adipose tissue (Suppl. 
Tab. 1a and b, tat1), presumably due to non-sense mediated decay (Maquat, 1995). 
    Mild phenotype under normal conditions.  tat1-/- pups grew normally and showed no 
visible phenotype when compared to their wild type (wt) littermates (Suppl. Fig. 1). 
Once adult, tat1-/- mice showed no body weight difference compared to wt (Tab. 1), they 
were fertile and gave birth to normal litters matching the expected Mendelian 
distribution (data not shown). AAAs transported by TAT1 such as L-Trp and L-Tyr are 
known to be precursors of serotonin, catecholamines and thyroid hormone. Thus, the 
absence of TAT1 transporter could potentially impact on neurotransmitter and thyroid 
hormone availability and lead to neurological disorders. Although no gross behavioural 
change was observed, the motor activity and coordination skills of the mice were tested 
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using a RotaRod test (Karl et al., 2003), which however showed no difference between 
tat1-/- and wt littermates (Fig. 2). In an attempt to exacerbate a potential phenotype, the 
same experiment was carried out after subjecting the mice to a low protein diet (7% 
casein) for 5 days, without revealing any difference between the two groups (data not 
shown). In order to visualize a potential abnormal behaviour of tat1-/- mice, the animals 
were video recorded in their normal cage prior and after fasting (data not shown) and 
their feeding and drinking behaviour recorded for 24 hours in metabolic cages (Tab. 1 
and Suppl. Tab. 2). Again, no difference was observed between tat1-/- mice and their wt 
littermates, exept for a slight increase in water intake and urinary volume that was larger 
than expected from the increased aminoaciduria (see below). A histological analysis of 
kidney, liver and intestinal segments on haematoxylin eosin stained sections did also not 
reveal any abnormality (Suppl. Fig. 2). A possible upregulation of other AA transporters 
was then investigated as compensatory mechanisms for TAT1 absence, but no 
significant change was noticed at the level of any tested AA transporter mRNA in 
various different organs (Suppl. Tab. 1a and b) nor at the level of B0AT1, TMEM27 and 
Lat2 proteins tested in kidney (data not shown). Also the carbohydrate metabolism did 
not appear to be perturbed, as indicated by a normal oral glucose tolerance test (Suppl. 
Fig. 3).  
    Altered homeostasis of aromatic amino acids. To assess the general impact of TAT1 
absence on AA homeostasis, we measured the plasma concentration of proteinogenic 
AAs. Surprisingly, the AAA plasma concentration of tat1-/- mice was 2, 3 and 7.5 times 
higher than in wt for L-Phe, L-Trp and L-Tyr, respectively (Fig. 3B). In contrast, many 
other AAs were significantly diminished in tat1-/- plasma (i.e. Gly, L-Ala, L-Met, L-Ser, 
L-Thr, L-Asn, L-Gln, L-Lys and L-Arg). In view of the mild general phenotype 
observed under normal protein diet (20%), the animals were challenged for 8 days with 
a high protein diet (chow containing 40% of casein). This treatment did not significantly 
affect their body weight and, besides the expected high urea and creatinine excretion 
and the lower urinary pH, only an increased fluid intake and urinary volume were 
observed that can be explained by the increased urea excretion (Table 1 and Suppl. Tab. 
2). Indeed, the urea concentration in the urine amounted to ~1350 mmol/l under normal 
diet and ~1600 mmol/l under high protein diet. tat1-/- mice displayed similar values as 
their wt littermates with a more pronounced effect on fluid intake. Upon switch to high 
protein diet, the plasma AAs remained stable in wt animals with the exception of the 
branched chain ones (BCAAs) that increased (Fig. 3A). In tat1-/- mice, the diet had a 
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similar effect as in wt mice and maintained the peculiar pattern observed under normal 
diet: an elevated concentration of AAAs and a low concentration of all other AAs, 
except the BCAAs, which followed the dietary effect observed in the wt (Fig. 3B).  
To further investigate the cause of the AA imbalance, free cytosolic AAs were 
measured in organs that represent the major reservoirs and metabolic sites: kidney, liver 
and skeletal muscles. The cellular concentrations of 5 representative AAs are depicted 
in Fig. 4. The AAAs L-Tyr and L-Trp displayed values strictly parallel to plasma in 
kidney and skeletal muscle. In contrast, in liver AAAs remained at the same lower 
concentration in tat1-/- as in wt. The organ concentrations of all non-aromatic AAs were 
similar in tat1-/- as in wt animals, as shown for L-Val and L-Leu (Fig. 4). One 
peculiarity is the high L-Phe values measured in kidney. This value might be related to 
the role of the kidney for the production of L-Tyr from L-Phe. 
    Altered epithelial amino acid transport. The analysis of 24 hours urine collected in 
metabolic cages showed that the dietary switch did not affect the AA excretion in wt 
animals (Fig. 5A). tat1-/- mice presented an aromatic aminoaciduria under normal 
protein diet that paralleled the high plasma values (Fig. 5B). However, under high 
protein diet, L-Tyr was found to be 64 times more abundant in tat1-/- than in wt urine 
and L-Trp and L-Phe, 95 and 9 times, respectively. Furthermore, many other neutral 
AAs were also present in higher amounts in tat1-/- urine (i.e. between 2 and 9 fold), 
including all other substrates of the Lat2-4F2hc broad selectivity neutral AA exchanger. 
This indicates that under normal protein diet tat1-/- mice had an almost normal or only 
slightly increased fractional excretion of all AAs. In contrast, the high protein diet 
provoked in tat1-/- mice a high urinary excretion of AAs corresponding to a major 
increase of their fractional excretion. This inability of the kidney to maintain a low 
fractional excretion was selective of AAs, since all other measured urinary parameters 
did not display any significant difference between tat1-/- and wt control mice (Tab. 1). 
Since TAT1 is expressed in the basolateral but not in the apical membrane of kidney 
proximal tubule, we hypothesize that the observed aminoaciduria might derive from an 
impaired basolateral export rather than from a defective apical import into epithelial 
cells. To verify this hypothesis, we used the isotopes 123I-2-I-L-Phe and 125I-2-I-L-Phe. 
These iodinated AAs are used as markers for oncologic imaging outside the brain, since 
their accumulation reflects the increased AA transport activity of cancer cells (Jager et 
al., 2001; Lahoutte et al., 2003). Their biodistribution has already been assessed and 
their validity demonstrated (Lahoutte et al., 2001; Lahoutte et al., 2003; Lahoutte et al., 
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2004). When tested in the Xenopus laevis oocytes expression system, the compound   
(2-I-L-Phe) was shown to efficiently compete for L-Phe transport, whether mediated by 
TAT1, Lat4 (Slc43a2) or Lat2-4F2hc (Suppl. Fig. 5). Exploiting microSPECT/CT 
technique, the 123I-2-I-L-Phe isotope was used for live imaging of its distribution 30 
minutes after intravenous injection (Fig. 6). Indeed a higher accumulation of the 
compound was clearly detected in both kidneys of the tat1-/- mouse (Fig. 6B). This 
qualitative observation was verified by the quantification of the accumulated counts 
after sacrifice (n = 3; Fig. 6C).  
Like the kidney proximal tubule, TAT1 is also expressed in the basolateral membrane 
of epithelial cells along the small intestine (Ramadan et al., 2006) (Suppl. Tab. 1). 
Therefore, AA transport was measured in everted gut sacs. A significant accumulation 
of 3H-L-Phe was observed in the enterocytes after 10 minute incubation at 37°C (Fig. 
7). Also a tendency for decreased net transepithelial transport into the serosal 
compartment was observed. These data support the hypothesis that TAT1 absence 
reduces the transepithelial transport of AAAs by decreasing their basolateral efflux. 
 
DISCUSSION 
Although the lack of TAT1 does not prevent the normal development and fertility of 
mice, the study of the newly developed tat1-/- mouse revealed a number of important 
functions of this low affinity AAA uniporter that impact on body AA homeostasis. For 
instance, the disruption of TAT1 is shown to prevent the liver of playing its central role 
for the metabolism of AAAs. It is indeed well known that the accumulation of AAs as 
response to high protein diet is counteracted by an increase in liver AA catabolism 
(Moundras et al., 1993). In particular, the liver is the major metabolic organ for the 
catabolism of AAAs (Schimassek & Gerok, 1965; Brosnan, 2003) and its failure causes 
an increase of AAAs in plasma (Fischer et al., 1976; Brosnan, 2003). This leads to a 
decrease of the BCAAs / AAAs ratio (Fischer ratio) and the consecutive increase of 
AAA uptake into the brain has been suggested to be a major cause of hepatic 
encephalopathy (James et al., 1979; Dejong et al., 2007). Here we show that plasma 
AAAs are stably elevated in tat1-/- mice regardless of the dietary load (Fig. 3). This 
increase is reflected in skeletal muscles, suggesting that TAT1 is not necessary for the 
AAA equilibration between plasma and this compartment (Fig. 4; Suppl. Tab. 1b). In 
contrast, in the liver of tat1-/- mice the intracellular AAA values are normal, indicating 
that the transport between the plasma that contains an elevated AAA concentration and 
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this organ is uncoupled (Fig. 8). The present data document that tat1 mediates the 
equilibration of the extracellular AAA concentration with the hepatocytes and suggests 
that the liver functions as sink for the AAAs and thereby sets their concentration and 
controls their body homeostasis.  
AAAs play important roles in the brain. Both increased and decreased levels are thought 
to impair brain function, as mentioned above for the increase in AAAs due to liver 
failure that contributes to hepatic encephalopathy. Dietary L-Trp restriction that was 
shown in mice to result in altered emotional response to stress and increased locomotor 
activity is one example in which a decreased level of AAAs leads to an alteration of 
brain functions (Uchida et al., 2005). However, a more recent study found no 
correlation between L-Trp depletion, central serotonin reduction and affective 
behavioural changes (van Donkelaar et al., 2010). The lack of signs of hepatic 
encephalopathy or behavioural disorders in tat1-/- suggests that the AAA concentration 
within the brain is normal or at a level that has no gross functional consequences. This 
suggests that the blood brain barrier function is intact, as expected based on our 
observation that tat1 is not expressed in mouse blood brain barrier endothelial cells 
(Lyck et al., 2009).  
The absence of behavioral and growth alterations also suggests that the lack of TAT1 
does not have a major impact on the function of thyroid hormone, although this 
transporter was shown to facilitate the diffusion of both T3 and T4 (Friesema et al., 
2008). Recent investigations from the laboratory of Heike Heuer indeed confirm that 
thyroid hormone metabolism is not altered in TAT1 null mice (personal 
communication). 
The placenta is another cellular barrier that expresses TAT1 but for which this 
transporter appears to be dispensable in laboratory conditions is (Meredith & Christian, 
2008). Indeed, tat1-/- foetus develop normally and tat1-/- female mice are normally 
fertile. After birth, tat1-/- mice maintain the capacity to absorb AAs from nutritional 
sources. This indicates that intestinal AA absorption and in particular the basolateral 
efflux of (aromatic) AAs from enterocytes is possible also in the absence of TAT1. We 
therefore tested for the upregulation of some other transporters that could compensate 
for the lack of TAT1. However, none of the other basolateral neutral AA transporters 
was found to be upregulated at the mRNA level in intestine and kidney, which 
suggested that the residual AAA transport capacity and potential paracellular transport 
can compensate for tat1 absence under normal diet.  
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An important finding is the massive loss of AAAs and more discrete loss of all substrate 
AAs of the neutral exchanger Lat2-4F2hc in the urine of tat1-/- mice under high protein 
diet (Fig. 5). This aminoaciduria implies that the maximal transport capacity for these 
AAs was exceeded in kidney proximal tubule and reveals the role of TAT1 for epithelial 
amino acid transport. Furthermore, it is suggested that this (aromatic) AA loss explains 
the fact that the tat1-/- mouse plasma AA concentration does not additionally change 
much under high protein diet. In our assay the urine was collected over 24 hours, 
whereas the blood was collected once (i.e. 3 hours after the switch to the inactive light 
phase). It is thus conceivable that under normal protein diet the AA transport rate is near 
the maximal transport capacity of the proximal tubule, already within the so-called 
splay, where some nephrons have not the capacity of reabsorbing all substrates. Since 
the plasma AA levels depend also on nutritional intake and are higher during the 
absorptive phase, under high protein diet a transient increase in blood AAs might cause 
the AA spillover. The urinary AA pattern (very high TAT1 substrates, increased Lat2-
4F2hc substrates) is in line with the suggested functional cooperation of the uniporter 
TAT1 with the exchanger Lat2-4F2hc for the net efflux of neutral AAs, as previously 
shown in the Xenopus laevis expression system (Ramadan et al., 2007). Interestingly, 
the loss of L-Phe in the urine was lower than that of L-Tyr and L-Trp. We hypothesize 
that this is due to the ability of another basolateral uniporter to transport L-Phe. Indeed, 
we have shown that Lat4 (Slc43a2) is also localized in the basolateral membrane of 
proximal kidney tubule cells and of small intestine enterocytes (Bodoy et al., 2005) 
(Mariotta, Guetg and Verrey unpublished data). This transporter was first described by 
Bodoy et al. in 2005 and shown to mediate the facilitated diffusion of BCAAs, L-Met 
and L-Phe and to a lesser extend L-Pro, L-Tyr and L-Trp. The presence of this other 
uniporter for essential amino acids and its selectivity might explain the differential 
urinary AAA pattern observed in tat1-/- mice (9-fold more L-Phe versus 64 and 95-fold 
more L-Tyr and L-Trp, respectively). Furthermore, Lat4 could to a large extent 
compensate for the absence of TAT1 in kidney and intestine and thus explain the mild 
phenotype of tat1-/- mice. The lack of Lat4 expression in the liver does on the other hand 
explain the fact that in the absence of tat1 expression, the liver cannot function as sink 
for aromatic amino acids (Bodoy et al., 2005). 
To verify that AAAs are efficiently imported luminally into transporting epithelial cells 
of tat1-/- mice, where they accumulate due to their inefficient basolateral export and 
consequently inhibit the apical transport, in vivo microSPECT/CT and ex vivo everted 
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gut sac experiments were performed. The results confirmed the accumulation of tracers 
inside the epithelial cells (Fig. 6 and 7). However, the everted gut sacs experiments did 
not allow us to detect a significant difference in the net transcellular flux of L-Phe (Fig. 
7: Serosa). This was due to a substantial residual permeability of the small intestine 
epithelium of tat1-/- mice for AAAs that might explain the normal growth of tat1-/- mice. 
This residual permeability is presumably due to a large extent to the contribution of the 
other uniporter Lat4, as mentioned above. We hypothesize however that a paracellular 
leak might also contribute to this permeability, as previously suggested for glucose and 
phosphate (Danisi & Murer, 1991; Pappenheimer, 1993; Ballard et al., 1995). 
A defect in tat1 has been predicted to be the cause of the blue diaper syndrome (Kim et 
al., 2001; Broer, 2008; Broer & Palacin, 2011). This syndrome was initially described 
by Drummond and co-workers in 1964 and appears to be caused by an excess of 
unabsorbed L-Trp in the intestinal tract (Drummond et al., 1964). We did not observe 
any symptom reminiscent of this syndrome in tat1-/- mice. Furthermore the amount of 
L-Trp found in the distal part of the small intestine was similar to wt (Suppl. Fig. 6) and 
much less than observed in Hartnup disorder (Singer and Verrey, unpublished results). 
 
In summary, the analysis of tat1-/- mice confirmed that a complex machinery of AA 
transporters functionally cooperates for the absorption and distribution of dietary AAs 
(Fig. 8). Our data further indicate that TAT1 exerts a major homeostatic function by 
equilibrating the concentration of AAAs between plasma and hepatocytes, where the 
AAAs are in turn catabolised. The functional impact of TAT1 absence becomes more 
evident under high protein diet, when the transport capacity of the kidney is exceeded 
such that a massive aromatic and also a neutral aminoaciduria appear that contributes in 
maintaining AA plasma homeostasis. We show that the aminoaciduria originates from 
an accumulation of AAs in the epithelial cells and we postulate that another basolateral 
uniporter, Lat4 (Slc43a2), compensates to a substantial extent for the lack of TAT1, in 
particular for driving the export function of the exchangers Lat2-4F2hc and y+Lat1-
4F2hc in small intestine and kidney proximal tubule. 
 
 
 
 
 
 
 
 Aromatic amino acid transport and homeostasis  
 
 13 
REFERENCES 
 
Augustin M, Sedlmeier R, Peters T, Huffstadt U, Kochmann E, Simon D, Schoniger M, 
Garke-Mayerthaler S, Laufs J, Mayhaus M, Franke S, Klose M, Graupner A, 
Kurzmann M, Zinser C, Wolf A, Voelkel M, Kellner M, Kilian M, Seelig S, 
Koppius A, Teubner A, Korthaus D, Nehls M & Wattler S. (2005). Efficient and 
fast targeted production of murine models based on ENU mutagenesis. Mamm 
Genome 16, 405-413. 
 
Ballard ST, Hunter JH & Taylor AE. (1995). Regulation of tight-junction permeability 
during nutrient absorption across the intestinal epithelium. Annu Rev Nutr 15, 
35-55. 
 
Bauwens M, Lahoutte T, Kersemans K, Caveliers V, Bossuyt A & Mertens J. (2007). 
D- and L-[123I]-2-I-phenylalanine show a long tumour retention compared with 
D- and L-[123I]-2-I-tyrosine in R1M rhabdomyosarcoma tumour-bearing 
Wag/Rij rats. Contrast Media Mol Imaging 2, 172-177. 
 
Bodoy S, Martin L, Zorzano A, Palacin M, Estevez R & Bertran J. (2005). 
Identification of LAT4, a novel amino acid transporter with system L activity. J 
Biol Chem 280, 12002-12011. 
 
Braun D, Wirth EK, Wohlgemuth F, Reix N, Klein MO, Gruters A, Kohrle J & 
Schweizer U. (2011). Aminoaciduria, but normal thyroid hormone levels and 
signalling, in mice lacking the amino acid and thyroid hormone transporter 
Slc7a8. Biochem J 439, 249-255. 
 
Broer S. (2008). Apical transporters for neutral amino acids: physiology and 
pathophysiology. Physiology (Bethesda) 23, 95-103. 
 
Broer S & Palacin M. (2011). The role of amino acid transporters in inherited and 
acquired diseases. Biochem J 436, 193-211. 
 
Brosnan JT. (2003). Interorgan amino acid transport and its regulation. J Nutr 133, 
2068S-2072S. 
 
Cynober LA. (2002). Plasma amino acid levels with a note on membrane transport: 
characteristics, regulation, and metabolic significance. Nutrition 18, 761-766. 
 
Danisi G & Murer H. (1991). Inorganic Phosphate Absorption in Small Intestine. in 
Comprehensive Physiology, John Wiley & Sons, Inc. 
 
Dejong CH, van de Poll MC, Soeters PB, Jalan R & Olde Damink SW. (2007). 
Aromatic amino acid metabolism during liver failure. J Nutr 137, 1579S-1585S; 
discussion 1597S-1598S. 
 
Drummond KN, Michael AF, Ulstrom RA & Good RA. (1964). The Blue Diaper 
Syndrome: Familial Hypercalcemia with Nephrocalcinosis and Indicanuria; a 
New Familial Disease, with Definition of the Metabolic Abnormality. Am J Med 
37, 928-948. 
 
 Aromatic amino acid transport and homeostasis  
 
 14 
Fernandez E, Torrents D, Chillaron J, Martin Del Rio R, Zorzano A & Palacin M. 
(2003). Basolateral LAT-2 has a major role in the transepithelial flux of L-
cystine in the renal proximal tubule cell line OK. J Am Soc Nephrol 14, 837-847. 
 
Fischer JE, Rosen HM, Ebeid AM, James JH, Keane JM & Soeters PB. (1976). The 
effect of normalization of plasma amino acids on hepatic encephalopathy in 
man. Surgery 80, 77-91. 
 
Friesema EC, Jansen J, Jachtenberg JW, Visser WE, Kester MH & Visser TJ. (2008). 
Effective cellular uptake and efflux of thyroid hormone by human 
monocarboxylate transporter 10. Mol Endocrinol 22, 1357-1369. 
 
Jager PL, Vaalburg W, Pruim J, de Vries EG, Langen KJ & Piers DA. (2001). 
Radiolabeled amino acids: basic aspects and clinical applications in oncology. J 
Nucl Med 42, 432-445. 
 
James JH, Ziparo V, Jeppsson B & Fischer JE. (1979). Hyperammonaemia, plasma 
aminoacid imbalance, and blood-brain aminoacid transport: a unified theory of 
portal-systemic encephalopathy. Lancet 2, 772-775. 
 
Karl T, Pabst R & von Horsten S. (2003). Behavioral phenotyping of mice in 
pharmacological and toxicological research. Exp Toxicol Pathol 55, 69-83. 
 
Keays DA, Clark TG, Campbell TG, Broxholme J & Valdar W. (2007). Estimating the 
number of coding mutations in genotypic and phenotypic driven N-ethyl-N-
nitrosourea (ENU) screens: revisited. Mamm Genome 18, 123-124. 
 
Kim DK, Kanai Y, Chairoungdua A, Matsuo H, Cha SH & Endou H. (2001). 
Expression cloning of a Na+-independent aromatic amino acid transporter with 
structural similarity to H+/monocarboxylate transporters. J Biol Chem 276, 
17221-17228. 
 
Lahoutte T, Caveliers V, Camargo SM, Franca R, Ramadan T, Veljkovic E, Mertens J, 
Bossuyt A & Verrey F. (2004). SPECT and PET amino acid tracer influx via 
system L (h4F2hc-hLAT1) and its transstimulation. J Nucl Med 45, 1591-1596. 
 
Lahoutte T, Caveliers V, Dierickx L, Vekeman M, Everaert H, Mertens J & Bossuyt A. 
(2001). In vitro characterization of the influx of 3-[125I]iodo-L-alpha-
methyltyrosine and 2-[125I]iodo-L-tyrosine into U266 human myeloma cells: 
evidence for system T transport. Nucl Med Biol 28, 129-134. 
 
Lahoutte T, Caveliers V, Franken PR, Bossuyt A, Mertens J & Everaert H. (2002). 
Increased tumor uptake of 3-(123)I-Iodo-L-alpha-methyltyrosine after 
preloading with amino acids: an in vivo animal imaging study. J Nucl Med 43, 
1201-1206. 
 
Lahoutte T, Mertens J, Caveliers V, Franken PR, Everaert H & Bossuyt A. (2003). 
Comparative biodistribution of iodinated amino acids in rats: selection of the 
optimal analog for oncologic imaging outside the brain. J Nucl Med 44, 1489-
1494. 
 
 Aromatic amino acid transport and homeostasis  
 
 15 
Loening AM & Gambhir SS. (2003). AMIDE: a free software tool for multimodality 
medical image analysis. Mol Imaging 2, 131-137. 
 
Lyck R, Ruderisch N, Moll AG, Steiner O, Cohen CD, Engelhardt B, Makrides V & 
Verrey F. (2009). Culture-induced changes in blood-brain barrier transcriptome: 
implications for amino-acid transporters in vivo. J Cereb Blood Flow Metab 29, 
1491-1502. 
 
Maquat LE. (1995). When cells stop making sense: effects of nonsense codons on RNA 
metabolism in vertebrate cells. RNA 1, 453-465. 
 
Meier C, Ristic Z, Klauser S & Verrey F. (2002). Activation of system L heterodimeric 
amino acid exchangers by intracellular substrates. Embo J 21, 580-589. 
 
Meredith D & Christian HC. (2008). The SLC16 monocaboxylate transporter family. 
Xenobiotica 38, 1072-1106. 
 
Moundras C, Remesy C & Demigne C. (1993). Dietary protein paradox: decrease of 
amino acid availability induced by high-protein diets. Am J Physiol 264, G1057-
1065. 
 
Nassl AM, Rubio-Aliaga I, Fenselau H, Marth MK, Kottra G & Daniel H. (2011). 
Amino acid absorption and homeostasis in mice lacking the intestinal peptide 
transporter PEPT1. Am J Physiol Gastrointest Liver Physiol 301, G128-137. 
 
Pappenheimer JR. (1993). On the coupling of membrane digestion with intestinal 
absorption of sugars and amino acids. Am J Physiol 265, G409-417. 
 
Park SY, Kim JK, Kim IJ, Choi BK, Jung KY, Lee S, Park KJ, Chairoungdua A, Kanai 
Y, Endou H & Kim DK. (2005). Reabsorption of neutral amino acids mediated 
by amino acid transporter LAT2 and TAT1 in the basolateral membrane of 
proximal tubule. Arch Pharm Res 28, 421-432. 
 
Pfeiffer R, Rossier G, Spindler B, Meier C, Kuhn L & Verrey F. (1999). Amino acid 
transport of y+L-type by heterodimers of 4F2hc/CD98 and members of the 
glycoprotein-associated amino acid transporter family. Embo J 18, 49-57. 
 
Ramadan T, Camargo SM, Herzog B, Bordin M, Pos KM & Verrey F. (2007). 
Recycling of aromatic amino acids via TAT1 allows efflux of neutral amino 
acids via LAT2-4F2hc exchanger. Pflugers Arch 454, 507-516. 
 
Ramadan T, Camargo SM, Summa V, Hunziker P, Chesnov S, Pos KM & Verrey F. 
(2006). Basolateral aromatic amino acid transporter TAT1 (Slc16a10) functions 
as an efflux pathway. J Cell Physiol 206, 771-779. 
 
Rossier G, Meier C, Bauch C, Summa V, Sordat B, Verrey F & Kuhn LC. (1999). 
LAT2, a new basolateral 4F2hc/CD98-associated amino acid transporter of 
kidney and intestine. J Biol Chem 274, 34948-34954. 
 
Schimassek H & Gerok W. (1965). Control of the levels of free amino acids in plasma 
by the liver. Biochem Z 343, 407-415. 
 Aromatic amino acid transport and homeostasis  
 
 16 
 
Seaton B & Ali A. (1984). Simplified manual high performance clinical chemistry 
methods for developing countries. Med Lab Sci 41, 327-336. 
 
Sugiura S, Kitagawa K, Tanaka S, Todo K, Omura-Matsuoka E, Sasaki T, Mabuchi T, 
Matsushita K, Yagita Y & Hori M. (2005). Adenovirus-mediated gene transfer 
of heparin-binding epidermal growth factor-like growth factor enhances 
neurogenesis and angiogenesis after focal cerebral ischemia in rats. Stroke 36, 
859-864. 
 
Uchida S, Kitamoto A, Umeeda H, Nakagawa N, Masushige S & Kida S. (2005). 
Chronic reduction in dietary tryptophan leads to changes in the emotional 
response to stress in mice. J Nutr Sci Vitaminol (Tokyo) 51, 175-181. 
 
van Donkelaar EL, Blokland A, Lieben CK, Kenis G, Ferrington L, Kelly PA, 
Steinbusch HW & Prickaerts J. (2010). Acute tryptophan depletion in C57BL/6 
mice does not induce central serotonin reduction or affective behavioural 
changes. Neurochem Int 56, 21-34. 
 
Vanhove C, Defrise M, Bossuyt A & Lahoutte T. (2011). Improved quantification in 
multiple-pinhole SPECT by anatomy-based reconstruction using microCT 
information. Eur J Nucl Med Mol Imaging 38, 153-165. 
 
Verrey F. (2003). System L: heteromeric exchangers of large, neutral amino acids 
involved in directional transport. Pflugers Arch 445, 529-533. 
 
Verrey F, Singer D, Ramadan T, Vuille-dit-Bille RN, Mariotta L & Camargo SM. 
(2009). Kidney amino acid transport. Pflugers Arch 458, 53-60. 
 
Wu G. (2009). Amino acids: metabolism, functions, and nutrition. Amino Acids 37, 1-
17. 
 
Wybenga DR, Di Giorgio J & Pileggi VJ. (1971). Manual and automated methods for 
urea nitrogen measurement in whole serum. Clin Chem 17, 891-895. 
 
 
Author contribution. Conception and design of the experiment (L.M., S.MR.C., T.L. 
and F.V.). Collection, analysis and interpretation of data (L.M., D.S., A.G., B.H., S.MR. 
C. and F.V.). Drafting and revising the article (L.M. and F.V.). All authors approved the 
final version. 
 
 Acknowledgments. The authors thank David Wolfer for his help in using the RotaRod, 
Hannelore Daniel for helpful discussions and the Functional Genomics Center Zurich 
(FGCZ) for the amino acid analysis. This work was supported by the Swiss National 
Science Foundation grant 31-130471 to FV.  
 Aromatic amino acid transport and homeostasis  
 
 17 
 
FIGURE LEGENDS 
 
FIGURE 1. TAT1 detection by immunofluorescence microscopy in sections of liver (A 
and B) and kidney (C and D). TAT1 is localized to the perivenous hepatocytes (A) and 
kidney proximal tubule cells (B) of wt tissues, whereas it is not detected in tat1-/- tissues 
(B and D). V: central vein, G: glomerulus, S1: proximal convoluted tubule segment S1.  
 
FIGURE 2. Locomotor and coordination capability of tat1-/- and wt littermates. Mice 
were tested with a RotaRod assay at accelerating and constant speed. Represented is the 
latency time before the first roll occurs (solid bars) and until first fall (open bars). Given 
are means ± SEM (n = 5). 
 
FIGURE 3. Free circulating amino acids in plasma: effect of high protein diet in wt 
mice (A) and altered amino acid profile in tat1-/- (B). A: absolute concentrations of 
amino acids measured in plasma of wild type mice subjected to normal (20%) and high 
(40%) protein diet. * indicates P<0.05. B: plasma amino acid concentrations in tat1 
knock out mice are shown relative to the values measured for their wild type littermates 
under the same diet. The horizontal line (y = 1) corresponds to the wt values. 
Represented are means ± SEM (n = 12). Groups were compared by one-way ANOVA, 
followed by Bonferroni posttest on selected pairs of columns. Values with letters are 
statistically different (P<0.05): 'a' and 'b' indicates difference of tat1-/- versus wt under 
normal protein diet and high protein diet, respectively, 'c' indicates difference between 
normal protein and high protein diet in tat1-/- mice, ns all comparison are not significant. 
 
FIGURE 4. Concentrations of free amino acids in plasma and in cytosol of different 
organs. PL: plasma, Liv: liver, Sk. m: skeletal muscles (i.e. M. gastrocnemius), Kid: 
kidney. Represented means ± SEM (n = 6). ** indicates P<0.01 and *** P<0.001 by 
unpaired Student t-test. More amino acids can be found in supplementary figure 6.  
 
FIGURE 5. Urinary amino acid profiles: the high protein diet has no effect on wt mice 
(A) but enhances the aminoaciduria in tat1-/- (B). A: total amino acids excreted in 24 
hours by wild type mice subjected to normal (20%) and high (40%) protein diet. B: 
amino acids excreted in tat1 knock out mice are shown relative to the values measured 
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for their wild type littermates under the same diet. The horizontal line (y = 1) 
corresponds to normalized wt values. The selectivity of known basolateral amino acid 
transporters measured in Xenopus laevis oocyte expression system is indicated below 
(References: [1] corresponds to (Ramadan et al., 2007), [2] to (Meier et al., 2002; Park 
et al., 2005) and [3] to (Bodoy et al., 2005)). +++ indicates high, ++ intermediate, + low 
and empty space no selectivity. Represented are means ± SEM (n = 12). Groups were 
compared by one-way ANOVA, followed by Bonferroni posttest on selected pairs of 
columns. Values with letters are statistically different (P<0.05): 'a' tat1-/- versus wt in 
NPD, 'b' tat1-/- versus wt in HPD, 'c' tat1-/- NPD versus HPD, 'd' wt NPD versus HPD, 
'ns' all comparison are not significant. 
 
FIGURE 6. 123I-2-I-L-Phe accumulation in kidney after i.v. injection. Fused micro-
SPECT/CT and micro-CT coronal scans of a wt (A) and a tat1-/- (B) mouse: the tat1-/- 
animal presented a clear accumulation of the compound in both kidneys, whereas 
kidney accumulation was low in wt. C: quantification of the biodistribution in different 
organs after dissection. Represented is the percentage of injected activity of 123I-2-I-L-
Phe in each tissue or organ per gram. Given are means ± SEM (n = 3). ** indicates 
P<0.01 by unpaired Student t-test. 
 
FIGURE 7. Significant accumulation of L-Phe in intestinal everted gut sacs. Everted 
sacs of tat1-/- and wt mouse small intestine were incubated at 37°C for 10 minutes in 
Krebs buffer containing 100 µM L-Phe and 3H-L-Phe tracer. Radioactivity was counted 
inside of the sacs (serosa) and in the tissue (epithelial cells). Transport rates were 
calculated and normalized to weight of tissue. Represented are means ± SEM (n ≥ 8). * 
indicates P<0.05 by unpaired Student t-test. 
 
FIGURE 8. Schematic representation of the impact of TAT1 deletion on body aromatic 
amino acid homeostasis. Black arrows indicate aromatic amino acid transport across cell 
membranes in the presence of TAT1 (black uniporter symbol). The red crosses and 
AAA labels indicate the situation in tat1-/- mice. The lack of TAT1-mediated aromatic 
amino acids diffusion into liver hepatocytes (major site of AAA metabolism) leads to a 
higher steady state AAA level in plasma. In the absence of TAT1, the transport of AAA 
is also decreased at the basolateral membrane of small intestine enterocytes and kidney 
proximal tubule cells and in skeletal muscle cells. However, AAA transport is 
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maintained across these membranes via (an) additional transporter(s) (empty uniporter 
symbol). Nonetheless, accumulation of aromatic amino acids was observed in these 
epithelial cells (indicated as red AAA). 
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TABLE 1: Urinary and physiological parameters of males measured in metabolic cages 
for 24 hours. 
Males 
Normal Protein Diet 
(20% Casein) 
High Protein Diet 
(40% Casein) 
 wt tat1-/- wt tat1-/- 
Urinary parameters:                   
pH 6.361 ± 0.03 6.46 ± 0.07 6.05 ± 0.06 c2 6.11 ± 0.02 d 
Creatinine (mg/24 hours) 0.174 ± 0.036 0.510 ± 0.088 1.150 ± 0.299 c 1.898 ± 0.316 d 
Creatinine (mg/dl) 40.2 ± 2.6 32.1 ± 2.9 22.8 ± 5.9 c 17.8 ± 0.9 
Urea (mg/dl)/crea (mg/dl) 166.7 ± 53.4 133.9 ± 23.4 332.1 ± 32.9 c 277.6 ± 29.5 d 
Na+ (mM)/crea (mg/dl) 8.58 ± 0.57 7.90 ± 0.49 9.45 ± 1.22 7.18 ± 0.98 
K+ (mM)/crea (mg/dl) 7.27 ± 0.26 6.38 ± 0.34 6.88 ± 0.71 5.38 ± 0.62 
Ca2+ (mM)/crea (mg/dl) 0.041 ± 0.001 0.048 ± 0.009 0.089 ± 0.008 c 0.078 ± 0.009 
Mg2+ (mM)/crea (mg/dl) 0.52 ± 0.06 0.36 ± 0.05 0.70 ± 0.13 0.59 ± 0.10 
Osmolality (mOsm/Kg H2O) 3148 ± 174 2260 ± 192 2660 ± 497 2072 ± 199 
 
                  
Urine volume (ml)/g BW 0.046 ± 0.005 0.086 ± 0.009 0.112 ± 0.019 c 0.164 ± 0.013 d 
Water intake (ml)/g BW 0.131 ± 0.014 0.244 ± 0.028 a 0.272 ± 0.023 c 0.362 ± 0.021 d 
Food intake (g)/g BW 0.142 ± 0.013 0.165 ± 0.010 0.144 ± 0.009 0.153 ± 0.009 
Feces (g)/g BW 0.021 ± 0.002 0.023 ± 0.001 0.020 ± 0.002 0.019 ± 0.002 
Body weight (g) 28.1 ± 1.0 25.7 ± 0.3 27.6 ± 0.8 26.2 ± 0.6 
Body weight (% change) 1.00 ± 0.00 1.00 ± 0.00 0.99 ± 0.01 1.02 ± 0.02 
 
1Given are means ± SEM. (n = 6). 2Groups were compared by one-way ANOVA, followed by 
Bonferroni posttest on selected pairs of columns. Values with letters are statistically different 
(P<0.05): 'a' indicates that tat1-/- and wt are significantly different under normal protein diet, 'c' that 
wt under normal and high protein diet are different and 'd' that tat1-/-  under normal versus high 
protein diet are different. No gender difference was observed. Female data can be found in 
supplementary Tab. 2. 
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